Approach to adrenal incidentalomas : a review by Imbroll, Miriam Giordano et al.
Malta Medical Journal, 32 (3): Pages (2020) 
http://mmsjournals.org/index.php/mmj  
 
The Editorial Board retains the copyright of all material published in the Malta Medical Journal. Any reprint in any form of any part will 
require permission from the Editorial Board. Material submitted to the Editorial Board will not be returned, unless specifically requested. 
Malta Medical Journal     Volume 32 Issue 03 2020           
REVIEW ARTICLE
Approach to adrenal incidentalomas: a review  
Miriam Giordano Imbroll, Josanne Vassallo, Mark Gruppetta 
Adrenal tumours are nowadays most often discovered incidentally, 
on imaging not performed for suspected adrenal disease that are 
termed adrenal incidentalomas. There are two questions clinicians 
need to explore: whether the lesion is benign or malignant (relying 
mostly on radiology) and whether it is functional or not (relying on 
biochemical tests). 
An unenhanced CT scan (CT without contrast) or MRI is the imaging 
modality of choice. However, if an incidentaloma is discovered on a 
CT with contrast, done for other reasons than suspected adrenal 
pathology, contrast washout may be helpful in diagnosing a benign 
lesion.  
Functional analysis in patients confirmed to have an adenoma or 
rarely an adrenal carcinoma should include tests to exclude cortisol 
excess, and in patients with hypertension, mineralocorticoid excess. 
The production of subtle amounts of cortisol, not enough to cause 
classical clinical features of Cushing syndrome, but enough to cause 
metabolic disturbances and, possibly increased mortality, has over 
recent years gained more attention. In those patients with suspected 
phaeochromocytoma, plasma free metanephrines or urinary 
fractionated metanephrines should be checked.  
This review, based on recent literature, discusses the evidence based 
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INTRODUCTION 
In clinical practice, tumours are the most 
frequently encountered pathologies of the 
adrenal gland. Such tumours may be either 
discovered incidentally or present with 
symptoms of hormonal excess.1 In recent 
years, the increasing use of abdominal imaging 
has resulted in a steep rise in the incidental 
discovery of adrenal lesions. These masses, 
detected by imaging studies originally not 
performed for suspected adrenal disease, have 
been coined ‘adrenal incidentalomas’.2  
The aetiology of adrenal incidentalomas varies 
and includes both benign and malignant 
lesions arising from the adrenal cortex or 
medulla. Metastatic deposits may also present 
as adrenal incidentalomas. The majority of 
primary adrenal lesions are hormonally non-
functional, however, a small proportion 
produce one or more adrenal hormone/s in 
excess.3 This excess production may occur 
irrespective of whether the lesion is benign or 
malignant.1 Over the last decade, there has 
been increasing awareness  that those with 
apparent non-functional tumours, that is, no 
classical signs and symptoms of hormonal 
excess, might exhibit mild autonomous 
cortisol hypersecretion without overt 
symptoms of Cushing syndrome.4 These 
patients possibly exhibit increased 
cardiovascular risk related to cortisol excess 
such as arterial hypertension, type 2 diabetes 
mellitus, insulin resistance, 
hypercholesterolaemia, obesity,5-9 increased 
vertebral fractures10 and increased mortality.11 
Adrenal incidentalomas raise challenging 
questions for both patients and their caring 
physicians. The aim of this review is to explore 
the latest evidence based approaches to 
adrenal incidentalomas and understand the 
pathway of investigations to be carried out 
when such an incidentaloma is discovered. The 
questions to be answered in the following 
review are: 
1. What are the imaging modalities of choice 
when dealing with adrenal 
incidentalomas? How often should 
imaging be carried out? 
2. How is a sinister lesion distinguished from 
a benign lesion? 
3. What functional tests should be carried 
out? 
CHARACTERISATION OF ADRENAL TUMOURS  
Once an adrenal lesion is incidentally 
discovered, there are two questions the 
clinician should consider (Figure 1):  
whether the lesion is benign or malignant 
(relying mostly on radiology) and, 
whether it is functional or not (relying on 
biochemical tests). 
Assessing for malignant potential: adrenal 
radiology 
Generally, 80-90% of adrenal incidentalomas 
are benign.1 Current morphological imaging 
modalities with computed tomography (CT) or 
magnetic resonance imaging (MRI) have 
proven to be a reliable means of excluding 
adrenal malignancy. Conversely, 
fluorodeoxyglucose (FDG)- positron emission 
tomography (PET)/CT is mainly used for 
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Figure 1 Algorithm for management of adrenal incidentaloma (Adapted Fassnacht et al.,[17]) 



















CT has a high spatial and quantitative contrast 
resolution. By measuring X-ray absorption of 
tissues, an assessment of tissue density can be 
made. This is measured in Hounsfield units 
(HU) which is an objective quantification of X-
ray absorption of tissues compared with water 
(HU value of 0). The threshold density for 
diagnosing a lipid rich, benign adrenal 
adenoma on a non-contrast CT is a density of 
less than 10HU (Figure 2).13 However, 
approximately 30% of benign lesions are 
considered lipid poor adenomas and therefore 
have an attenuation of >10HU on non-contrast 
CT. Other lesions such as malignant lesions and 
phaeochromocytomas also have high density 
on non-contrast CT, creating an area of overlap 
with lipid poor adenomas.14-16 A density of >10 
HU on non-contrast CT of the tumour has a 
high sensitivity of 100% (95%CI 91-100%) but 
poor specificity of 72% (95%CI 60-82%) for 
detecting malignancy.12 In other words, an 
incidentaloma discovered on non-contrast CT 
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Figure 2 A right sided adrenal lesion (arrowed) measuring 32 x 27mm with characteristics in 
 keeping with a typical lipid rich adrenal adenoma: 
 a. CT pre-contrast showing a density of 3HU 
 b. CT at 60 seconds after contrast: 67HU 
 c. CT at 15 minutes after contrast (delay): 27HU 
   Absolute washout 63% 










Contrast enhancement CT with washout 
Adenomas are unique in their perfusion 
pattern. They take up intravenous CT contrast 
quickly but also lose contrast rapidly; a 
phenomenon termed ‘contrast enhancement 
washout’.13-15 On the other hand, malignant 
lesions and phaeochromocytomas, usually 
demonstrate washout of contrast medium at a 
slower pace. Adrenocortical carcinomas 
demonstrate heterogenous enhancement 
with predominance at the periphery, and 
centrally there are often areas of cystic 
changes or necrosis. About 30% demonstrate 
intra-tumoral calcification.13 
Phaeochromocytomas are usually 
characterised by areas of degeneration, 
necrosis, fibrosis, calcification and cystic 
changes. Adrenal metastasis show overlapping 
features with adrenocortical carcinoma and 
phaeochromocytoma.  Hence in a patient with 
a history of extra-adrenal malignancy, 
metastasis should be included in the 
differential diagnosis, especially if lesions are 
bilateral or have shown rapid growth in size.15 
‘Contrast washout values’ utilise this unique 
property to further characterise adrenal 
lesions which on non-contrast scans have a 
density of more than 10HU. Attenuation 
measurements are done in the following three 
phases: before injecting contrast (unenhanced 
density (HU)), at 60 seconds following contrast 
injection (early enhanced density (HU)) and 
after 15 minutes of injecting contrast (delayed 
density (HU)). This allows for the calculation of 
the relative contrast enhancement washout 
and absolute contrast enhancement washout 
according to the following formulae: relative 
washout = (early enhanced density of lesion 
(HU) – delayed density of lesion (HU)) / (early 
enhanced density (HU)) x 100%. Absolute 
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washout = ((early enhanced density (HU) – 
delayed density (HU)) / (early enhanced 
density (HU) – unenhanced density (HU)) x 
100%.13  A relative washout of >40% and an 
absolute washout >60% is suggestive of a 
benign adrenal adenoma (Figure 2), whereas a 
relative and/or absolute washout value of less 
than 40% and 60% respectively is suggestive 
of malignancy, including metastasis or 
phaeochromocytoma.15-16 Sensitivity of CT 
contrast enhanced washout was found to be 
100% (95% CI 75-100%) and specificity 92% 
(95% CI 62-100%), in patients with no history 
of underlying malignancy.12 
MRI scan 
Chemical shift imaging is an MRI technique 
used to identify adenomas from other adrenal 
lesions.16 Within magnetic fields, protons in 
water vibrate at a slightly different frequency 
than protons in lipid, thus fat and water 
protons oscillate in and out of phase with 
respect to one another. Lipid rich adrenal 
adenomas usually lose signal intensity on out-
of-phase images compared with in-phase 
images, whereas malignant lesions and 
phaeochromocytomas (and lipid poor 
adenomas) remain unchanged. The advantage 
of this modality over CT is that it avoids 
radiation exposure and iodine based contrast, 
together with its better tissue resolution. 
According to the same meta-analysis by Dinnes 
et al., sensitivity is 86% (95%CI 31-99%) and 
specificity is 85% (95% CI 73-93%).12 
18F-FDG-PET 
18F-FDG-PET is a nuclear medicine modality 
that provides quantitative tomographic 
images after intravenous injection of a beta-
radiation-emitting radiotracer (18-Fluorine) 
used to label 2-deoxy-D-glucose rendering 
fluoro-deoxyglucose (18F-FDG). Both glucose 
and deoxyglucose enter cells via glucose 
transporters, but while glucose undergoes 
further enzymatic breakdown, deoxyglucose 
does not and becomes trapped inside the cells. 
Cancer cells have an increased requirement for 
glucose, so they take up more glucose and 
deoxyglucose, which can then be measured, 
giving a standard clinical measurement index; 
the standardised uptake index (SUV).16 This 
test has a sensitivity of 100% (95%CI 78-100%) 
and specificity of 96% (95% CI 57-100%) for 
detecting malignancy in those patients 
without previous extra-adrenal malignancy. In 
those with previous malignancy, sensitivity 
drops to 82% (95% CI 41-97%) whereas 
specificity is similar to that in patients without 
previous malignancy.12 
Assessing for hormonal excess 
Hormonal evaluation is recommended to be 
performed on all incidentally found 
adrenocortical adenomas, suspected 
adrenocortical carcinomas and 
phaeochromocytomas (Figure 1). A detailed 
clinical evaluation including history and 
examination might help to detect signs and 
symptoms of hormone excess.17 The most 
frequent lesion is a non-functional adrenal 
adenoma; comprising 85% of all lesions.18 
These lesions do not need further 
interventions.17 Functional adrenocortical 
adenomas include those producing excess 
cortisol and mineralocorticoid, and 
phaeochromocytomas which are characterised 
by excess metanephrines and catecholamines 
secretion. Adrenocortical carcinomas may 
produce glucocorticoids, mineralocorticoids 
and/or adrenal androgens. 
Cortisol excess 
In recent years further interest has centred on 
those adrenal adenomas which produce subtle 
amounts of cortisol which are not enough to 
manifest clinically with overt features of 
82
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cortisol excess (round plethoric complexion, 
acne, hirsutism, centripetal obesity, proximal 
muscle weakness, mood disturbance and 
menstrual disturbance). This phenomenon, 
labelled ‘autonomous cortisol secretion’, in 
fact, is the most frequent endocrine 
dysfunction in adrenal adenomas,17 ranging 
from 1 to 29%. Various thresholds to diagnose 
cortisol excess have been quoted,1,19 but 
according to recent European guidelines, a 
9am serum cortisol level of less than 50nmol/l, 
after 1mg dexamethasone (overnight 
dexamethasone suppression test (ODST)) 
given at 11pm the night before, excludes the 
diagnosis of autonomous cortisol secretion. A 
level between 51 and 138nmol/l suggests 
‘possible autonomous cortisol secretion’ 
whilst a level of >138nmol/l supports the 
diagnosis of ‘autonomous cortisol secretion’. 
Overt Cushing syndrome is defined as a level 
of cortisol following dexamethasone of 
>138nmol/l plus classical clinical 
manifestations of Cushing syndrome.17  
Patients with Cushing syndrome have 
increased multisystem morbidity and 
mortality, and surgery should therefore be 
considered in the first instance (Figure 1).17 In 
a study by Dekkers et al., patients with Cushing 
syndrome (including both ACTH dependent 
(pituitary) and ACTH independent), mortality 
was twice as high in the Cushing syndrome 
group when compared to controls (HR 2.9, 
95%CI 1.8-2.9). The risk was also increased for 
venous thromboembolism (HR 2.6, 95%CI 1.5-
4.7), myocardial infarction (HR 3.7, 95%CI 2.4-
5.5), stroke (HR 2.0 95%CI 1.3-3.2), peptic 
ulcers (HR2.0 95%CI 1.1-3.6), fractures (HR 1.4, 
95%CI 1.0-1.9), and infections (HR 4.9, 95%CI 
3.7-6.4). These risks were similarly increased, 
irrespective of whether they had pituitary or 
adrenal source of cortisol excess.20 
 
Studies have also demonstrated that low 
grade autonomous cortisol secretion might be 
associated with certain comorbidities, 
including hypertension, glucose intolerance 
and type 2 diabetes,6 ischaemic heart disease 
and dyslipidaemia,9 obesity,8 osteoporosis10 
and increased mortality.11 However, a recent 
meta-analysis, showed only low-to-moderate-
quality evidence pointing in favour of 
adrenalectomy in patients with autonomous 
cortisol secretion, on the cardiovascular risk 
factors, when compared with conservative 
management.21 Therefore, surgery, in patients 
with autonomous and possible autonomous 
cortisol secretion, should be done on an 
individual basis taking into account age, 
degree of cortisol excess, general health, 
comorbidities and patient’s preference (Figure 
1).17 
Mineralocorticoid excess 
Primary aldosteronism is characterised by an 
inappropriately high level of aldosterone in 
proportion to sodium status, relative 
autonomy from the regulators of its secretion, 
namely angiotensin II and plasma potassium 
concentration, and no suppression on loading 
with sodium.22 Patients with an adrenal 
incidentaloma and hypertension are 
recommended to undergo a 3-step process 
which includes screening, confirmatory 
testing, followed by subtype classification for 
detection of an aldosterone secreting 
adenoma.22 Plasma aldosterone/renin ratio 
(ARR) is the screening test proposed in the 
guidelines. When primary aldosteronism is 
suspected based on the ARR, a confirmatory 
test (oral sodium loading, saline infusion, 
fludrocortisone suppression test or captopril 
test) will further enhance the diagnosis in 
those contemplating surgery. In these 
patients, subtype classification with the help 
of imaging and possibly adrenal vein sampling 
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(AVS) might be indicated to identify unilateral 
as opposed to bilateral disease. Surgery is the 
preferred option in  patients with unilateral 
disease and who are fit for surgery, with the 
rest being treated with a mineralocorticoid 
receptor antagonist.22 
Patients with primary aldosteronism have a 
higher cardiovascular morbidity and mortality, 
compared to age- and sex-matched patients 
with the same degree of hypertension, 
unrelated to mineralocorticoid excess.23 They 
have increased target organ damage and 
cardiovascular events than patients with 
essential hypertension who have  similar risk 
profiles.24 There is also an ongoing debate on 
whether treatment with adrenalectomy is 
superior to treatment with mineralocorticoid 
receptor antagonists. Recent studies have 
shown that in a unilateral aldosterone 
secreting adenoma, surgery is superior in 
reducing left ventricular mass, as it reverses 
the ventricular wall thickening as well the 
general enlargement of the left ventricular 
cavity.25 
Combined glucocorticoid and mineralocorticoid 
excess 
Some case reports have reported co-secretion 
of excess glucocorticoids and aldosterone.26 A 
recent study by Arlt et al., showed that a large 
proportion of patients do in fact co-secrete 
these two hormones.27 In this study, mass 
spectrometry steroid metabolome was used 
on a 24 hour urine collection and this 
technique detected that glucocorticoid 
metabolite excretion, in patients with primary 
aldosteronism, is a frequent occurrence 
(P<0.001) with levels as high as in patients with 
overt adrenal Cushing syndrome. This might 
shed light as to why treatment with 
adrenalectomy is superior to 
mineralocorticoid receptor antagonists in 
patients with presumed isolated aldosterone 
excess.   
Catecholamine excess 
Phaeochromocytomas form part of a broad 
group of tumours derived from the neural 
crest of the sympathetic or parasympathetic 
nervous system, collectively termed 
phaeochromocytoma/paragangliomas (PPGL). 
These tumours commonly secrete one or more 
of the following catecholamines: adrenaline, 
noradrenaline and dopamine. Surgical 
resection of PPGLs is recommended in the first 
instance.28 
Untreated excess catecholamine secretion is 
associated with increased cardiovascular 
morbidity and high mortality.29 To prevent the 
morbidity and mortality associated with this 
tumour and because there are cases of ‘silent’ 
phaeochromocytomas, where catecholamine 
secretion may be intermittent, any adrenal 
incidentaloma, especially those not having 
characteristics of an adenoma on CT or MRI, 
should be screened for a possible 
phaeochromocytoma. Screening with plasma 
free metanephrines or urinary fractionated 
metanephrines is recommended.28 In 
phaeochromocytomas, a diagnosis of 
malignancy is only established with the 
detection of extra-adrenal metastasis. 
Another reason why phaeochromocytoma 
detection is actively sought is, that at least one 
third of cases, have a disease-causing germ-
line mutation. Therefore, detecting a 
phaeochromocytoma might result in earlier 
diagnosis and possibly screening of other 
family members. Genetic studies are 
recommended in all patients with 
phaeochromocytoma.28 Some forms of 
phaeochromocytomas, especially those 
associated with the gene succinate 
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dehydrogenase sub unit B (SDHB) have a 
higher malignant potential (40%).30 
The latest guidelines on adrenal 
incidentalomas17 recommend measuring 
plasma-free or 24-hr urine fractionated 
metanephrines, in all patients with adrenal 
incidentaloma, but point out that it may be 
reasonable to avoid such biochemical testing 
in patients who have an adrenal incidentaloma 
with unenhanced attenuation of less than 
10HU. A recent study by Canu et al. further 
supports this. Out of 376 
phaeochromocytomas for which unenhanced 
attenuation data were available, 99.5% had an 
attenuation of >10 HU (374 patients). The two 
exceptions (0.5%), were found to have an 
unenhanced attenuation of exactly 10 HU, 
which lies just within the range of ≤10 HU that 
would suggest a diagnosis of adrenocortical 
adenoma.  In this study, however, assessment 
with contrast washout was unreliable for 
ruling out phaeochromocytoma.31 
Androgen excess 
The adrenal cortex also secretes androgens, 
however screening for androgen excess is not 
recommended in patients with an adrenal 
adenoma on a routine basis.17 The only 
recommended instance when measurement of 
adrenal androgens (dehydroepiandrosterone 
sulphate (DHEA-S), androstenedione, 17-
hydroxyprogesterone and testosterone in 
women and oestradiol in men and 
postmenopausal women) is suggested, is when 
suspecting adrenocortical carcinoma (Figure 
1).17 
FOLLOW UP OF ADRENAL LESIONS 
Current recommendations by the European 
Society of Endocrinology Clinical Practice 
guidelines, in collaboration with the European 
Network for the Study of Adrenal tumours, 
suggest against repeat imaging in patients 
with an adrenal incidentaloma less than 4cm 
which on initial assessment had benign 
features on imaging studies.17 Before these 
guidelines were issued, common practice was 
that if a lesion was thought to be benign at 
baseline, further follow up investigations were 
recommended to detect the occurrence of 
malignancy in an adrenal incidentaloma 
displaying typical features of adrenocortical 
adenoma at initial imaging studies. Hormonal 
evaluation was suggested to be carried out 
annually for 4 years.1 This reasoning was 
challenged, because amongst more than 2,300 
patients included in follow up studies, there 
was nearly no report of adrenal malignancy 
occurrence in those incidentalomas thought to 
be benign at initial evaluation.17 However, 
most patients with adrenal incidentalomas 
>4cm in diameter have undergone 
adrenalectomy in the past, and the literature 
on follow-up of non-operated large adrenal 
incidentalomas is scarce. Thus, some experts 
argue that at least one follow up imaging after 
6-12 months might be considered in lesions 
not operated upon and, thought to be benign 
at diagnosis, but are >4cm.17 
CHANGE IN SIZE OF ADRENAL LESION  
One of the main dilemmas in managing 
patients with adrenal incidentalomas is when 
there is an increase in size in a lesion which was 
deemed to be benign on initial imaging. In the 
consensus statement by the Italian Endocrine 
Association (AME), it was concluded that in a 
group of patients with adrenal incidentalomas 
followed up for an average of 4 years, 5-20% 
showed mass enlargement >1cm and/or 
appearance of a mass in the contralateral 
adrenal gland. Mass enlargement was 
generally limited to 1-2 cm increase in 
diameter over a period of 1-3 years. However, 
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even in those tumours which exhibited a 
pattern of slow growth, malignant 
transformation was still very low (<1 out of 
1000).1 The presence or absence of endocrine 
abnormalities at the time of diagnosis cannot 
be used as a predictor of possible increase in 
tumour size during follow-up, because even 
non-functional adenomas were documented 
to have increased in size.32 Moreover, 
shrinkage, or even complete resolution of a 
mass was reported in around 4% of cases, most 
often those with a cystic component, 
haematomas or adrenal pseudo-tumours.32 
FOCUS ON ADRENOCORTICAL CARCINOMA 
Adrenocortical carcinoma (ACC) is a rare 
malignancy with an estimated incidence of 0.7-
2 cases/million/habitants/year.33 Most often it 
presents with either steroid hormone excess 
or an abdominal mass, although in 15% of 
cases, ACC is discovered incidentally. 
Prognosis in patients with ACC is poor.34 
Urine steroid metabolomics in the context of 
ACC and beyond 
Despite the numerous tests and imaging 
procedures proposed to distinguish benign 
from malignant and functional from non-
functional tumours, definite diagnosis is 
sometimes difficult to ascertain, especially in 
those tumours presenting in an atypical way. 
Mass spectrometry based steroid profiling is 
also being proposed for detecting 
adrenocortical malignancy.35 This steroid 
metabolomic approach is based on the fact 
that, although theoretically most (60-70%) of 
adrenocortical carcinomas are biochemically 
active, conventional hormonal detection is 
negative in most cases. This may be explained 
by the inefficient steroid production in 
adrenocortical carcinoma. This novel 
technique has proven to be efficient in 
detecting these steroid precursors in urine.  
The top nine most discriminatory markers have 
been identified and may be used in clinical 
practice in the future.35 
CONCLUSION 
With the advent of newer imaging modalities, 
there has been a steep rise in the pick-up rate 
of adrenal incidentalomas over recent years. 
Lately, strong evidence has emerged on the 
workup of such lesions focusing on two main 
areas: assessing for malignancy by relying 
mainly on radiology and assessing 
functionality (relying on biochemical tests) in a 
parallel fashion as outlined in Figure 1. 
Since adrenal incidentalomas are encountered 
by clinicians across different fields, in this 
article we have provided a succinct account on 
the management of such incidentally 
discovered lesions, keeping in mind that 
malignancy and functionality are two 
characteristics which need to be sought out 
independently, by following the recently 
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